Affiliated Heyu Pharmaceuticals completed the first patient dosing of the Phase I clinical trial of the innovative PRMT5*MTA inhibitor ABSK131.

Zhito Financial APP news, Heyu-B (02256) announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Biomedical) announced that its research-oriented innovative PRMT5*MTA inhibitor ABSK131 has completed dosing the first patient in a phase 1 clinical trial in MTAP-deficient advanced/metastatic solid tumor patients. In March 2025, ABSK131 obtained the IND approval from the China National Medical Products Administration Drug Evaluation Center. In December 2024, ABSK131 obtained the IND approval from the U.S. Food and Drug Administration.